[A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy].
A 44-year-old female with premenopausal advanced breast cancer had been treated with a combination of LH-RH analogue and tamoxifen as primary endocrine therapy following adjuvant chemotherapy. Forty-seven months after operation, because metastases of contralateral axillary lymph nodes were detected by computer tomography, she was treated with a combination of LH-RH analogue and aromatase inhibitor as second-line endocrine therapy. During the 16-month administration of LH-RH analogue and aromatase inhibitor, she was been well without new metastatic lesions and maintained a high quality of life.
Baba
Shinji
S
Dept. of Surgery, Shinkawabata Hospital.
Oji
Yuto
Y
Teramoto
Makoto
M
Kawabata
Kazuya
K
Saito
Atsuo
A
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D047072:Aromatase Inhibitors / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D017273:Goserelin / Q000008:administration & dosage*; D006801:Humans; D008207:Lymphatic Metastasis; D017697:Premenopause; D013629:Tamoxifen / Q000008:administration & dosage
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen; D017273:Goserelin